Brief: Nykode Therapeutics Enters Clinical Collaboration With MSD
Dec 6 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH
MSD TO
EVALUATE VB10.16 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)
IN PATIENTS WITH HPV16-POSITIVE HEAD AND NECK CANCER
* UNDER TERMS OF AGREEMENT, MERCK WILL SUPPLY KEYTRUDA.
NYKODE
RETAINS ALL COMMERCIAL RIGHTS TO VB10.16 WORLDWIDE
Source text for Eikon: ID:nObiBD6Hqa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026